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New participant stratification and 
combination of urinary biomarkers 
and confounders could improve 
diagnostic accuracy for overactive 
bladder
Sepinoud firouzmand1, Ladan Ajori2,3 & John S. Young  1*
Overactive bladder (OAB) is a highly prevalent symptom complex characterised by symptoms of urinary 
urgency, increased frequency, nocturia, with or without urge incontinence; in the absence of proven 
infection or other obvious pathology. The underlying pathophysiology of idiopathic OAB is not clearly 
known and the existence of several phenotypes has been proposed. Current diagnostic approaches are 
based on discordant measures, suffer from subjectivity and are incapable of detecting the proposed 
OAB phenotypes. In this study, cluster analysis was used as an objective approach for phenotyping 
participants based on their OAB characteristic symptoms and led to the identification of a low OAB 
symptomatic score group (cluster 1) and a high OAB symptomatic score group (cluster 2). Furthermore, 
the ability of several potential OAB urinary biomarkers including ATP, ACh, nitrite, MCP-1 and IL-5 and 
participants’ confounders, age and gender, in predicting the identified high OAB symptomatic score 
group was assessed. A combination of urinary ATP and IL-5 plus age and gender was shown to have 
clinically acceptable and improved diagnostic accuracy compared to urodynamically-observed detrusor 
overactivity. Therefore, this study provides the foundation for the development of novel non-invasive 
diagnostic tools for OAB phenotypes that may lead to personalised treatment.
Idiopathic overactive bladder (OAB) is defined by the presence of bothersome symptoms of urinary urgency, 
increased frequency, nocturia, with or without urge incontinence in the absence of proven infection or other 
obvious pathology1. The prevalence of OAB ranges between 9% to 43% and 7% to 27% in female and male, 
respectively2.
The initial assessment of OAB includes documentation of OAB signs and symptoms, and exclusion of other 
diseases that present with some overlapping symptoms2. OAB studies to date have used varying combinations 
and/or severity of the main four OAB characteristic symptoms to identify patients for OAB studies’ inclusion and 
exclusion criteria. These differences across studies are considered as a challenge2 for interpretation, replication 
or clinical implementation of observed findings from these studies. This has resulted in attrition of well-needed 
new diagnostic methods such as many unsuccessful OAB-specific biomarker studies, and new drug development 
studies. Recently amended American Urological Association/Society of Urodynamics, Female Pelvic Medicine 
and Urogenital Reconstruction (AUA/SUFU) Guidelines on non-neurogenic OAB diagnosis and treatment2 
highlight the need for better OAB stratification and the use of validated standardised measures for reporting 
subjective outcomes in clinical studies. Therefore, there is an unmet need for an objective OAB symptom-based 
classification approach.
Cluster analysis is a statistical approach used to reveal natural groupings within a population and to catego-
rise individuals with similar characteristics into meaningful clusters. It has been used as such for the objective 
stratification of complex medical3 and psychiatric disorders4. As OAB is a symptom complex, subjecting its char-
acteristic symptoms to cluster analysis may be used as an objective approach for participant stratification, but 
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also may reveal the existence of groups of participants with specific combination and/or severity of symptoms 
(i.e. phenotypes of OAB5) that otherwise are not detectable using subjective human-based symptom analysis. 
Therefore, in this study, cluster-analysis was applied to data collected on the four main OAB characteristic symp-
toms and associated bothersome scores in order to assess the ability of such analysis in objectively identifying any 
meaningful groupings amongst participants.
Furthermore, the need for identification and development of OAB-specific biomarker(s) was another criterion 
highlighted in AUA/SUFU guidelines2. From the studies to date, the urinary levels of several biomarkers have 
shown to be altered in OAB patients6. The main drawback of these studies is a lack of sensitivity and specificity6. 
Previous attempts to elucidate urinary biomarkers for OAB have used univariate statistical analyses; thus neglect-
ing many influencing variables and factors, such as the probable synergistic effects of combining biomarkers and 
confounders. The prevalence7 and severity8 of OAB increases with age. Some studies have reported its higher 
prevalence in female than male9,10, whereas others found no difference across genders7,11. Therefore, the impact 
of confounders such as age and gender is worthy of consideration in biomarker discovery analysis. Hence, mon-
itoring a combination of biomarkers and participants’ confounders may produce tools with improved diagnostic 
accuracy. Therefore, in this study, we assessed the individual and combinational abilities of six candidate OAB 
urinary biomarkers plus participants’ confounders (including age and gender) in predicting groups identified 
using the new symptom-based OAB classification approach. These biomarkers included adenosine triphosphate 
(ATP)12; acetylcholine (ACh)13; nitric oxide (NO)14 and its oxidation product, nitrite; interleukin-5 (IL-5); and 
monocyte chemoattractant protein 1 (MCP-1)15). The six chemical biomarkers were chosen because previous 
research had shown their changes in association with OAB.
Overall, this study aimed to better stratify patients based on OAB symptoms and subsequently characterise 
stratified groups based on urinary biomarkers.
Results
Participants. This study and all its procedures were approved by the National Research Ethics Service (NRES) 
Committee South Central Berkshire (REC reference: 13/SC/0501). All research was performed in accordance 
with procedures and regulations at the University of Portsmouth. Written informed consent was obtained from all 
participants. According to the performed power analysis, a minimum of 84 participants was required to provide 
an 80% power to detect a correlation of 0.3 between the symptom scores and each urine biomarker at 5% two-
sided significance level. One hundred and thirteen self-selecting volunteers with or without symptoms of OAB 
were recruited to allow for those excluded according to the inclusion/exclusion criteria and for a number of drop-
outs. Amongst 113 recruited participants, ten were diagnosed with yeast/bacterial infection or haematuria; four 
participants failed to complete one or some of the questions associated with the main four OAB characteristic 
symptoms on the ICIQ-OAB questionnaire and four did not meet the inclusion criteria and therefore excluded. 
Hence, 95 participants were eligible to be involved in the further analyses (Fig. 1).
Distribution of OAB characteristic symptom and bothersome scores. The frequency distri-
butions of eligible participants’ OAB characteristic symptoms and associated bothersome scores are shown in 
Fig. 2a–e,f–j, respectively. Distributions were right-skewed, where no apparent bimodal or multimodal distribu-
tions suggestive of distinct groupings (e.g. suggestive of OAB phenotypes and asymptomatics) was noticeable.
Figure 1. Flow diagram of participants’ selection, subsequent tests and analysis performed. ICIQ-
OAB = International consultation on incontinence questionnaire - overactive bladder. asee Methods and 
Materials section for inclusion and exclusion criteria.
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Phenotyping participants based on their reported profile of OAB characteristics using cluster 
analysis. Two-step cluster analysis was used to identify any natural groupings amongst participants’ OAB 
related characteristics including symptom scores, symptom associated bothersome scores and symptom plus 
associated bothersome scores (Supplementary Table S2).
In general, two natural groups were identified based on all the different aspects of the participants’ OAB asso-
ciated characteristics (Supplementary Table S2). Fourteen participants failed to complete one or some bother-
some associated questions, therefore, groups identified based on participants’ OAB characteristic symptom scores 
only (n = 95) were chosen for further analyses. Amongst 95 participants, 36 and 59 participants were assigned by 
the cluster analysis to clusters 1 and 2, respectively (Table 1). Urgency was identified as the main cluster predictor 
component and was followed by incontinence, frequency and nocturia, in order of importance (Supplementary 
Table S2). In other words, urgency (the key OAB symptom16) was the primary factor accounting for the differ-
ences between the two groups. The distribution of urinary symptom scores amongst the two identified clusters 
is reported in Table 1 and depicted in Fig. 3. No significant differences were observed between the proportion of 
male and female between the two groups (Table 1). Participants in cluster 2 had statistically significantly higher 
urgency (p ≤ 0.0001); incontinence (p ≤ 0.0001); frequency (p = 0.0048) and nocturia (p = 0.0115) scores and 
were significantly older (p = 0.0079, male participants in both clusters were significantly older than their female 
Figure 2. Frequency distributions of ICIQ-OAB urinary symptom scores and associated bothersome scores of 
eligible participants. (a–e) Frequency distributions (n = 95) of OAB characteristic symptom scores of eligible 
participants. (f–j) Frequency distributions (n = 81) of OAB symptom associated bothersome scores of eligible 
participants. 14 participants left one or some of the symptom associated bothersome questions blank. See 
Supplementary Table 1 for ICIQ-OAB questionnaire.
Cluster description Cluster 1 Cluster 2 p value
n 36 59
Gender (F/M) 20/16 41/18 nsa
Age, mean (range) 
(yrs) 49 (21–90)
b 56 (22–93) 0.0079c
Urgencyd, median 
(IQR) 0 (0.00–0.00)
0.25 
(0.25–0.37)  ≤0.0001
c
Incontinenced, median 
(IQR)
0.0 
(0.00–0.00)
0.20 
(0.00–0.20)  ≤0.0001
c
Frequencyd, median 
(IQR)
0.33 
(0.00–0.33)
0.33 
(0.33–0.67) 0.0048
c
Nocturiad, median 
(IQR)
0.00 
(0.00–0.25)
0.25 
(0.00–0.25) 0.0115
c
Table 1. Description of clusters identified using Two-step cluster analysis. n = number of participants in each 
cluster; ns = not significant; IQR = Interquartile range, 1st quartile-3rd quartile. aZ-test was used for comparison. 
bOne missing age value, n = 35 for cluster 1. cMann-Whitney test. dSymptoms scores were range standardised on 
a 0 to 1 scale.
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counterparts (data not shown)) compared to those in cluster 1 (Table 1). Not all the participants in cluster 1 were 
truly asymptomatic; that is, with a symptom score of zero for all the four OAB-associated symptoms. This was 
expected as the recruitment of a truly asymptomatic age-matched (i.e. 22–93 yrs) group is challenging given the 
prevalence of lower urinary tract symptoms in nearly two-thirds of adults7. Therefore, subsequent analyses were 
based on the identified groups, i.e. low OAB symptomatic score group (cluster 1) and high OAB symptomatic 
score (cluster 2).
Comparison of the urinary concentrations of the individual biomarkers between the two iden-
tified groups. A comparison of the urinary concentrations of each biomarker between the two identified 
groups is reported in Supplementary Fig. 1. There was no statistically significant difference in the levels of indi-
vidual urinary biomarkers between the two identified groups. This may be due to the fact that there are changes 
to biomarker levels already in the low OAB symptomatic score group (cluster 1) compared to urine from truly 
asymptomatic participants, and these biomarkers do not change much more as symptoms become more severe. 
Alternatively, because our comparison is not between two extreme ends of the OAB symptom severity spectrum 
(i.e. asymptomatic vs. severe OAB), differences in individual associated biomarker concentrations in our com-
parison are small and not statistically different. Therefore, such biomarkers - used individually - would not be 
suitable to identify initial stages of OAB development.
The ability of urinary biomarkers and confounders in predicting the high OAB symptomatic 
score group from the low OAB symptomatic score group. The individual ability of the candidate uri-
nary biomarkers (including ATP, ACh, NO, Nitrite, MCP-1 and IL-5), and confounders (age and gender) in pre-
dicting the identified high OAB symptomatic score group (cluster 2) from the low OAB symptomatic score group 
(cluster 1) was assessed using binary logistic regression (Supplementary Table S3). Age was the only parameter 
that was shown to have statistically significant prediction power (p = 0.041, Supplementary Table S3). In order 
to assess whether the addition of other parameters would increase the prediction power of age, 23 combination 
models were developed by incorporating candidate urinary biomarkers and gender (Supplementary Table S3). 
Amongst all the developed logistic models, seven models including combination 1 (age + gender, p = 0.020); 
combination 10 (age + gender + Il-5, p = 0.011); combination 12 (age + gender + ACh, p = 0.039); combination 
14 (age + gender + IL-5 + ACh, p = 0.015); combination 15 (age + gender + IL-5 + ACh + ATP, p = 0.045); com-
bination 17 (age + gender + IL-5 + ATP, p = 0.026) and combination 18 (age + gender + IL-5 + NO, p = 0.024) 
were also shown to have statistically significant prediction powers (Supplementary Table S3). All the developed 
models passed goodness of fit test (Hosmer-Lemeshow test in Supplementary Table S3).
The diagnostic accuracy of the developed logistic models in distinguishing the high OAB symptomatic score 
group (cluster 2) from the low OAB symptomatic score group (cluster 1) was assessed by ROC analysis (Fig. 4). 
Amongst the seven combination models, only six models (i.e. combinations 10; 12; 14; 15; 17 & 18) were shown 
to have clinically acceptable diagnostic powers (i.e. 0.7 ≤ AUC < 0.8, Fig. 4). Age, despite having a statistically 
significant prediction power, did not have clinically acceptable diagnostic power (AUC = 0.663, Fig. 4). Age and 
gender combined have an AUC of 0.670 with a sensitivity and specificity both of 66%. ROC curves for the logistic 
models without statistically significant prediction powers are also shown in Supplementary Fig. 2.
Furthermore, the performance (i.e. positive predictive value (PPV) and negative predictive value (NPV)) of 
the six combination models that were shown to have clinically acceptable diagnostic powers were assessed based 
on the prevalence range of OAB in female (between 9% to 43%) and male (between 7% to 27%)2 and was com-
pared to urodynamically-observed detrusor overactivity (DO) (Table 2). All the six logistic models were shown 
to have higher NPV and PPV values compared to DO at both lower and higher end of the prevalence range for 
both female and male (Table 2).
Figure 3. Radar plot of the distributions of the participants’ OAB characteristic symptom scores amongst 
the identified clusters. The distribution of participants’ responses to each OAB symptom question was range 
standardised on a 0–1 scale were 0 represents the lowest and 1 represents the highest symptom severity for 
each OAB characteristic symptom, i.e. the centre of the plots represents the lowest symptom scores and the 
outermost layer of the plots represents the highest symptom scores. See Table 1 for the measures of central 
tendency (i.e. median) of each OAB characteristic symptom in each cluster.
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Predicting the probability of an individual being in the identified high OAB symptomatic score 
group. Combination 17 was shown to have the highest PPV (21%, 67% for female and 17%, 50% for male) and 
NPV (96%, 75% for female and 97%, 86% for male) values compared to the other logistic models or urodynamic 
DO (Table 2), therefore, an equation predicting the likelihood of the identified high OAB symptomatic score 
group (cluster 2) was constructed based on the combination 17 (Table 3). Henceforth, by measuring urinary levels 
of IL-5 and ATP and entering their creatinine-normalised values plus values for age and gender in the formula, 
Figure 4. Receiver-operating characteristic curves (ROCs). (a) Age; (b) Combination 1 = Age + Gender; 
(c) Combination 10 = Age + Gender + IL-5; (d) Combination 12 = Age + Gender + ACh; (e) Combination 
14 = Age + Gender + IL-5 + ACh; (f) Combination 15 = Age + Gender + IL-5 + ACh + ATP; (g) Combination 
17 = Age + Gender + IL-5 + ATP; (h) Combination 18 = Age + Gender + IL-5 + NO. AUC = Area under the 
ROC curve; Value in parenthesis = standard error; Bold value = 0.7 ≤ AUC < 0.8 meaning predictive model 
has clinically acceptable discriminatory power; Solid line = prediction model curve; Grey diagonal dashed 
line = chance line.
Based on maximum Youden Index (J)
Based on prevalence range of OAB in female Based on prevalence range of OAB in male
Lower end 9% Top end 43% Lower end 7% Top end 27%
Predictive model Pcluster 2 cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
Combination 10 0.51 67 69 18 96 62 74 14 97 44 85
Combination 12 0.46 81 53 15 97 57 79 12 97 39 88
Combination 14 0.46 74 63 16 96 60 76 13 97 42 87
Combination 15 0.56 65 76 21 96 67 74 17 97 50 85
Combination 17 0.56 66 76 21 96 67 75 17 97 50 86
Combination 18 0.51 67 69 18 96 62 74 14 97 44 85
Urodynamic DOa 54 68 14 94 56 66 11 95 38 80
Table 2. Clinical performance of the constructed OAB predictive models based on the prevalence range of 
OAB in female and male. Pcluster 2 = Probability of an individual being in the identified high OAB symptomatic 
score group; PPV = Positive predictive value; NPV = Negative predictive value. aSensitivity and specificity 
values for urodynamic test was obtained from Digesu et al.23 study where the presence of DO was used as a 
marker for diagnosing those presenting with OAB symptoms.
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the probability of an individual being in the identified high OAB symptomatic score group (pcluster 2) could be 
calculated.
Discussion
OAB is a symptom complex that may significantly impact sufferers’ quality of life including their physical and 
mental health, social, sexual, economical and professional lives17,18. Idiopathic OAB is a symptom-based diagno-
sis, however, a consensus regarding the symptom severity or combination necessary for accurate OAB diagnosis 
is lacking. AUA/SUFU identified that inconsistent combinations of OAB symptoms used as inclusion criteria 
across studies are challenging for interpretation, and they have recommended better stratification of OAB and 
phenotyping of its characteristic symptoms2. In this study, we aimed to objectively stratify patients based on OAB 
symptoms and subsequently characterise stratified groups based on urinary biomarkers.
In order to stratify, cluster analysis was used to objectively phenotype participants based on their reported 
profile of OAB characteristic symptoms and/or associated bothersome scores. Despite programming the statis-
tical analysis to detect the existence of a maximum number of 15 groups, only two groups were identified, where 
one had statistically significantly higher OAB characteristic symptom scores compared to the other one. Urgency 
was the main factor accounting for differences between the two identified groups, followed by incontinence, 
frequency and nocturia. Previous studies, such as Cinar et al.19 and Hall et al.20, took the similar approach for 
clustering participants based on their urological symptoms, however, these studies were based on a broad range 
of lower urinary tract symptoms, rather than focusing on symptoms associated with a distinct type of urological 
disease/symptom complex. Peyronnet et al. 2019 suggested the existence of several OAB phenotypes based on 
the different underlying mechanisms and pathophysiological cofactors5. Therefore, understanding the changes 
that occur across different phenotypes of OAB requires an approach that can identify such subpopulations at 
early developmental stages in order to enable researchers to monitor temporal pathophysiological changes. To 
the best of authors’ knowledge, this is the first study that has applied such an objective approach to identify OAB 
phenotypes. In addition, in order to increase the sensitivity of such approach in detecting changes that occur at 
the initial stages across OAB phenotypes, participants were selected from those that were expected to have mild to 
moderate OAB characteristic symptoms. In other words, the involvement of those participants at the higher end 
of the OAB symptom spectrum was kept to a minimum, in order to avoid their potential effect on cluster analysis 
through masking the identification of potential indiscernible changes that occur at the initial developmental 
stages across OAB-phenotypes. Future studies should involve those across the entire range of the OAB symptom 
spectrum.
Exclusion of other diseases that present some overlapping symptoms with OAB is part of the initial OAB diag-
nostic process. In this study, this was achieved by having detailed exclusion criteria (see Methods and Materials) 
and through the use of a comprehensive range of tests to exclude UTI including microscopic examination, dip-
stick urinalysis and chromogenic UTI medium test. According to AUA/SUF, the use of urine culture as part of the 
routine urinalysis for OAB is not necessary unless indication of infection is found during dipstick or microscopic 
examination, or may be performed at the discretion of the clinician2. However, due to the deficiencies in UTI 
diagnostic methods21 and as UTI is considered as the most commonly misdiagnosed condition among women 
with OAB22, all the participants in this study were subjected to a combination of tests to ensure UTI exclusion.
However, limitations of the current stratification method deserve mention. Similar to the current initial 
subjective OAB classification, the current objective participant stratification method was based on participants’ 
self-reported symptoms, meaning diagnosis is based on subjective measures. The use of other diagnostic meas-
ures, such as urodynamics, are not recommended by AUA/SUFU in the initial diagnostic workup of uncom-
plicated OAB2. In addition, the association between invasive means of urodynamically-demonstrable detrusor 
overactivity (DO) and OAB symptoms remains questionable, with half of patients with OAB symptoms not 
exhibiting DO, whereas DO was observed in two-thirds of those without any OAB symptoms23–25. Furthermore, 
according to the recently published European Association of Urology guidelines on assessment and nonsurgical 
management of urinary incontinence (UI), the evidence of clinical benefit of urodynamically-observed DO with 
the UI treatment outcome remains inconsistent26. Therefore, non-invasive surrogates such as urinary biomarkers, 
if proven to be sensitive and specific for OAB-phenotypes, might be the key to solve the subjectivity issues asso-
ciated with OAB diagnosis.
Following the identification of two distinct OAB symptom-associated groups, we assessed the ability of several 
potential OAB urinary biomarkers including ATP, ACh, nitrite, MCP-1 and IL-5 and participants’ confounders 
such as age and gender, in differentiating the high OAB symptomatic score group from the low OAB sympto-
matic score group. Previous discovery studies based on a single putative OAB biomarker have suffered from 
issues of sensitivity and specificity27, perhaps attributable to the limitations of univariate statistical approaches i.e. 
each biomarker was considered discretely and independent of participants’ confounders or other biomarkers28. 
Predictive model OAB prediction equation
Combination 17
Probability of an individual being in the high OAB symptomatic score group 
(pcluster 2) = 1/1 + e−X, where X = (−3.090) + 5.393 x subject’s ageb + 1.797 x Gender 
(Female = 1, Male = 0) + 34.767 × [IL-5/Cr]b + (−562.743) x [ATP/Cr]b
Table 3. OAB predictive equation. e = exponential-e; Cr = Creatinine, urinary biomarker value needs to be 
normalised to urinary creatinine concentration before being entered in the equation. bVariable(s) needs to be 
range standardised before being entered into the equation, age to 120 yrs old, IL-5/Cr to 100 and ATP/Cr to 
0.000001. Standard errors (SE) for constants and coefficients are reported in Table S4.
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Multivariate statistical approaches were used in this study to explore the synergistic effects of combining con-
founders and candidate biomarkers as a discriminatory means for the identified high OAB symptomatic score 
group (cluster 2). Twenty-three combination models, comprising confounders and urinary biomarkers, were 
developed; of which six models were shown to have both satisfactory prediction and diagnostic (i.e. sensitivity 
and specificity) abilities in distinguishing the high OAB symptomatic score group (cluster 2) from the low OAB 
symptomatic score group (cluster 1). Age and gender themselves are reasonable predictors of OAB; that is, they 
differentiate between the low OAB symptomatic score group (cluster 1) and the high OAB symptomatic score 
group (cluster 2) with an AUC of 0.67 and a sensitivity and specificity both of 66%. The diagnostic power of age 
and gender is not unexpected given a well-documented increase in OAB prevalence with age7 and a greater prev-
alence in females9. However, age and gender are confounders for different types of LUTS, therefore, a combina-
tion of age, gender and OAB biomarkers improve the ability to detect OAB. In this study the addition of urinary 
biomarkers improved the diagnostic power by up to 6% (i.e. to an AUC of up to 0.73; Table 2). In comparison to 
age and gender, some combinations are more sensitive (e.g. Combination 12, 81% sensitivity; Table 2) and oth-
ers more specific (e.g. Combination 17, 76% sensitivity; Table 2). More work is required to refine the biomarker 
combinations in order to achieve an improved diagnostic power. To the best of authors’ knowledge, the current 
study has for the first time assessed the predictability and discriminatory powers of the combination of potential 
urinary biomarkers and participants’ confounders for OAB using multivariate statistical methods. Peyronnet et al. 
2019 suggested that OAB phenotypes are possibly not exclusive and are likely to overlap, which may explain the 
reason behind success of some combination therapies for some OAB patients5. The same rationale could be true 
in the case of the diagnosis of OAB phenotypes, where a single biomarker could not have the adequate discrimi-
natory power, therefore, a combination of several parameters could improve diagnostic accuracy.
As no gold standard OAB diagnostic method is currently available, the clinical performance of the six com-
bination models was compared to urodynamically-observed DO. All the six combination models were shown 
to have better performance compared to urodynamically-observed DO. Amongst these combination models, 
combination 17, i.e. a combination of age, gender, ATP and IL-5, was shown to have the highest PPV and NPV 
values, and were similar to the performance of urine-based tests for other diseases such as bladder carcinoma29 
or prostate cancer30. An equation based on combination 17 was constructed to predict the likelihood of the iden-
tified high OAB symptomatic score group. By measuring the urinary levels of IL-5 and ATP and entering their 
creatinine-normalised values, in addition to age and gender, in to the formula, the possibility of an individual 
being in the identified high OAB symptomatic score group could be predicted. This study provides the foundation 
for the development of novel non-invasive diagnostic tools for OAB, where the effects of biomarkers and key OAB 
confounders31 could be considered in conjunction.
Limitations. By ruling out similarly-presenting conditions at the point of recruitment (see ‘Exclusion crite-
ria’) and by performing urine pathology testing, we had hoped to recruit participants with a spectrum of lower 
urinary tract symptoms attributable to OAB. We acknowledge, however, that the ICIQ-OAB questionnaire lacks 
the ability to differentiate between different types of incontinence such as urge urinary incontinence, mixed uri-
nary incontinence or stress incontinence. Although all the participants in this study with incontinence (i.e. an 
incontinence score of >0) had other OAB characteristic symptoms, more needs to be done in the future to dif-
ferentiate between different types of incontinence. Furthermore, we cannot rule out the possibility that OAB was 
secondary to outflow obstruction. Future studies should therefore either involve participants with a broad range 
of OAB symptoms in order to allow the identification of further OAB phenotypes, and should be extended to 
include more participants and those with mixed urinary incontinence or, alternatively, include more rigorous 
recruitment criteria to exclude other possible overlapping conditions such as stress incontinence and polyuria. In 
addition, the involvement of other potential urinary biomarkers such as nerve growth factor32 and brain-derived 
neurotrophic factor33 and other OAB influencing factors such as body mass index34, smoking and alcohol intake 
should be considered. Furthermore, the clinical utility and performance of prediction algorithms should be tested 
in large, longitudinal studies.
Conclusion
This study aimed to address the need for better OAB stratification. By using cluster analysis, we objectively phe-
notyped participants based on their urinary symptoms. This approach could be used in future to better stratify 
OAB phenotypes. Furthermore, the identification of combinations of urinary biomarkers that are associated with, 
and unique to, our stratified groups, provides the means to identify those phenotypes. We focus on one combina-
tion (comprising biomarkers and confounders) that together have improved diagnostic accuracy (sensitivity and 
specificity) and clinical performance (positive and negative predictive values) for OAB compared to the current 
available methods. When tested in large, longitudinal studies, this approach and its findings offer the potential for 
the development of more accurate and non-invasive diagnostic tools.
Methods and Materials
Recruitment of participants. This study and all its procedures were approved by the National Research 
Ethics Service (NRES) Committee South Central Berkshire (REC reference: 13/SC/0501). All methods were car-
ried out in accordance with the guidelines and regulations of the University of Portsmouth. Written informed 
consent was obtained from all participants. Power analysis was performed in order to indicate the required num-
ber of participants for this study. A total of 113 volunteer participants (between 2014 and 2016) were recruited 
via volunteer sampling from the University of Portsmouth; the Briars Greensleeves Homes Trust-Isle of Wight; 
the National Federation of Women’s Institutes and Portsmouth Pensioners’ Association. Participants were asked 
to complete a validated OAB questionnaire (the International consultation on incontinence questionnaire 
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- overactive bladder (ICIQ-OAB)) (Supplementary Table S1) and to provide a fresh midstream urine sample. 
Collected samples and data were made anonymous using an ID code system.
Inclusion criteria. Male or female participants aged ≥18 and able to give informed consent for participation in 
the study.
Exclusion criteria. Male or female participants aged ≤18; taking any medication for OAB; unable to give 
informed consent; diagnosed with neurologic disease (stroke, MS, Parkinson’s disease, spinal cord injury); have 
history of uterine, cervical, vaginal or urethral cancer; history of cyclophosphamide use or any type of chemical 
cystitis; history of benign or malignant bladder tumours; have had Botulinum toxin injections, neuromodulation 
or augmentation cystoplasty.
Urine pathology tests. Microscopic examination, dipstick urinalysis and chromogenic urinary tract infection 
(UTI) medium test were immediately performed on a small proportion of each collected urine sample. Any sam-
ple with positive test result was excluded from the study. The remainder of the urine sample was centrifuged (at 
4000 rpm, 10 mins, at 4 °C), separated into cell pellet and supernatant and stored at −80 °C before being subjected 
to biomarker analyses.
Biomarker assays. The urinary (cell-free) concentrations of the candidate biomarkers were measured 
using ENLITEN® ATP Assay System Bioluminescence Detection Kit (FF2000, Promega, UK); Amplex® Red 
Acetylcholine/Acetylcholinesterase assay (Invitrogen™ Molecular Probes™, A12217, UK); Sievers Nitric Oxide 
Analyser (NOA™ 280i, Analytix, UK); BD OptEIATM human MCP-1 enzyme-linked immunosorbent assay 
(ELISA) (559017, BD biosciences, UK); Quantikine® human IL-5 ELISA Kit (R&D Systems®, D5000B, UK) and 
the OptEIATM Human IL-5 ELISA Set (555202, BD biosciences, UK) according to the manufacturers’ instructions.
Creatinine assay. Urinary creatinine (Cr) was measured using the Cayman Creatinine (urinary) 
Colourimetric Assay Kit (CAY500701, Cambridge Bioscience, UK), following the manufacturer’s instructions. 
All urinary biomarker values were normalised to corresponding Cr concentrations.
Statistical analysis. Cluster analysis. TwoStep cluster analysis was performed using IBM SPSS statistics 
22.0 on the range standardised (0–1 scale) ICIQ-OAB questionnaire data, including symptom scores; symptom 
associated bothersome scores and symptom plus associated bothersome scores. The software was programmed to 
automatically identify a maximum number of 15 clusters. Clusters formed based on symptom scores were chosen 
for further analyses due to the higher number of involved participants.
Binary logistic regression. The ability of the candidate biomarkers and participants’ confounders (age and gen-
der), individually or in combination, in predicting the probability of an individual being in the identified high 
OAB symptomatic score group (cluster 2) was studied using binary logistic regression analysis (IBM SPSS statis-
tics 22.0). Each variable was range standardised to the highest possible number that could be measured for any 
one human (and even for some biomarkers the considered value was much higher) i.e. age was range standardised 
to 120; ATP/Cr to 0.000001; ACh/Cr to 0.1; NO/Cr to 20000; Nitrite to 200; MCP-1/Cr to 100 and IL-5/Cr to 100. 
Therefore, any measured value in the future could be range standardised to the same values used in this study and 
consequently could be placed in the generated logit equation to estimate the probability of an individual being in 
the identified high OAB symptomatic score group (cluster 2).
Receiver Operating Characteristic (ROC), positive predictive value (PPV) and negative predictive value 
(NPV). ROC curve analysis (IBM SPSS statistics 22.0) was used in order to evaluate the discriminatory power 
of the generated OAB prediction models using predicted probability values generated by logistic regression anal-
yses. The following area under the curve (AUC) criteria was used to determine the discriminatory power of the 
generated predictive models: 0.5 ≤ AUC < 0.6: no discriminatory power; 0.6 ≤ AUC < 0.7: poor discriminatory 
power; 0.7 ≤ AUC < 0.8: acceptable discriminatory power; 0.8 ≤ AUC < 0.9: excellent discriminatory power and 
0.9 ≤ AUC ≤ 1: outstanding discriminatory power35. The optimal cut-off values of the predicted probability of 
an individual being in the high OAB symptomatic score group (pcluster 2) for the selected predictive models were 
determined as the value with the maximum Youden Index (J = sensitivity + specificity – 1). PPV and NPV of each 
predictive model was calculated based on its sensitivity and specificity at the optimal cut-off value and based on 
the prevalence range of OAB in female (between 9% to 43%) and male (between 7% to 27%)2, and was compared 
to those for urodynamically-observed detrusor overactivity (DO) from Digesu et al. 2003 study23. ROC curve 
analysis was not performed as part of the Digesu et al. 2003 study, hence, data on the AUC and optimal cut-off 
values were not available.
Equation predicting the probability of an individual being in the identified high OAB symptomatic score group. An 
equation to predict the probability of an individual being in the identified high OAB symptomatic score group 
(cluster 2) was constructed based on the constant and coefficients values obtained from the logistic regression 
analysis for combination model 17.
Data availability
The data that were generated and/or analysed for this study are available from the corresponding author upon 
request.
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